Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, double-blind, placebo-controlled, parallel-group, multicentre trial to investigate Durogesic [fentanyl] in comparison to placebo in subjects with moderate to severe pain induced by osteoarthritis of the hip or the knee, who are in need of and waiting for hip or knee replacement

Next Previous
X
Search
Trial Profile

Randomised, double-blind, placebo-controlled, parallel-group, multicentre trial to investigate Durogesic [fentanyl] in comparison to placebo in subjects with moderate to severe pain induced by osteoarthritis of the hip or the knee, who are in need of and waiting for hip or knee replacement

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2006

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Janssen

    • Most Recent Events

    • 24 Jul 2006 Status change
    • 18 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top